Skip to main content

Market Overview

ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment

Share:
ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment
  • ADC Therapeutics SA (NYSE: ADCThas scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two prior lines of therapy.
  • Following a priority review in November with a review date of May 21, Zylonta’s accelerated nod comes a month ahead of schedule.
  • The company will have to prove its clinical benefit in a confirmatory study to maintain its marketing approval.
  • The approval comes just under a year after ADC went public, raising $233 million.
  • The FDA endorsed the drug based on data from a Phase 2 trial, LOTIS 2. The drug turned in an overall response rate of 48.3%, and, for those who responded, the median duration of response was 10.3 months. More than 24% of patients experienced a complete response.
  • Price Action: ADCT shares are up 5.72% at $24.58 in the premarket session on the last check Monday.
 

Related Articles (ADCT)

View Comments and Join the Discussion!

Posted-In: Briefs DLBCLBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com